Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Consensus PT from Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been given an average recommendation of “Hold” by the ten analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $9.33.

Several research firms have recently weighed in on FULC. Leerink Partners reaffirmed a “market perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. Leerink Partnrs cut Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald cut shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. Finally, HC Wainwright reiterated a “neutral” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in FULC. Charles Schwab Investment Management Inc. boosted its holdings in Fulcrum Therapeutics by 223.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock valued at $2,032,000 after acquiring an additional 393,202 shares during the period. Braidwell LP purchased a new position in shares of Fulcrum Therapeutics during the third quarter valued at about $3,817,000. Assenagon Asset Management S.A. purchased a new position in shares of Fulcrum Therapeutics during the 2nd quarter worth approximately $3,084,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Fulcrum Therapeutics in the 3rd quarter worth approximately $474,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at approximately $721,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Trading Up 7.9 %

Fulcrum Therapeutics stock opened at $4.35 on Friday. Fulcrum Therapeutics has a 1-year low of $2.86 and a 1-year high of $13.70. The firm has a market capitalization of $234.63 million, a PE ratio of -14.03 and a beta of 2.14. The firm’s 50 day simple moving average is $3.59 and its 200 day simple moving average is $5.80.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.